Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: R>G> who wrote (3006)	7/12/1998 10:19:00 AM
From: R>G>	Read Replies (4) \| Respond to of 5402

Update From Parke Davis Headquarters In Ann Arbor From the Ann Arbor News The three-year $270 million expansion project is fueled by blockbuster sales of two drugs-Lipitor and rezulin. 1996 research and development $465 million 1997 research and development $573 million 1998 research and development $700 million approximately For Warner Lambert, (parent company of Parke-Davis) next year's resarch and development will exceed 1 billion dollars. Looks like some of these companies have deep pocket's for research.